At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
Pemetrexed +4 moredrug
Likely dose
Pemetrexed 500 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory Phase 2 Study of Pemetrexed/Cisplatin as Pre-operative Chemotherapy in the Treatment of Stage IIIAN2 Nonsquamous Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Pemetrexed, Cisplatin, and 3 other interventions for Non Small Cell Lung Cancer. Completed, enrolled 19 participants across 7 sites.
Detailed Summary
The purpose of this trial is to assess how well the combination of pemetrexed with cisplatin can reduce tumor size.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesItaly
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2010
Enrollment StartNov 2010
Primary CompletionJul 2013
Study CompletionApr 2016
TodayJul 2026
First PostedJul 19, 2010
Enrollment StartNov 1, 2010
Primary CompletionJul 1, 2013
Study CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 16.0 years ago
Interventions
Pemetrexeddrug
500 milligram per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
Cisplatindrug
75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
Folic Aciddrug
Administered orally.
Vitamin B12drug
Administered Intramuscular injection.
Dexamethasonedrug
Administered orally.